Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of azacitidine in chronic myelomonocytic leukemia
ISRCTN21428905Phase 2Completed
- Sponsor
- Leeds Teaching Hospitals NHS Trust
- Start
- Nov 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of azacitidine in chronic myelomonocytic leukemia (CMML), sponsored by Leeds Teaching Hospitals NHS Trust. Primary endpoints: Safety and tolerability and Overall response rate. Started Nov 2009; status: completed.
02
Drugs
azacitidine
03
Conditions
chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on ISRCTN21428905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN21428905.